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Cardiomyopathies due to mutations in human b-car-
diac myosin are a significant cause of heart failure,
sudden death, and arrhythmia. To understand the
underlying molecular basis of changes in the con-
tractile system’s force production due to such muta-
tions and search for potential drugs that restore force
generation, an in vitro assay is necessary to evaluate
cardiac myosin’s ensemble force using purified pro-
teins. Here, we characterize the ensemble force of
human a- and b-cardiac myosin isoforms and those
of b-cardiac myosins carrying left ventricular non-
compaction (M531R) and dilated cardiomyopathy
(S532P) mutations using a utrophin-based loaded
in vitro motility assay and new filament-tracking soft-
ware. Our results show that human a- and b-cardiac
myosin, as well as the mutants, show opposite
mechanical and enzymatic phenotypes with respect
to each other. We also show that omecamtiv
mecarbil, a previously discovered cardiac-specific
myosin activator, increases b-cardiac myosin force
generation.
INTRODUCTION
With the advent of technologies to easily obtain the complete
sequence of the human genome, an exponential increase will
be seen in our understanding of the underlying genetics that
lead to human disease. Where we have a deep understanding
of the biochemical and biophysical basis of the machineries
and pathways involved in those genetic changes, the develop-
ment of modern therapeutics that specifically target the actual
machinery and pathways altered by individual mutations will de-
mand increasing attention. Prime examples of such genetic dis-
ease are hypertrophic (HCM), dilated (DCM), and left ventricular
non-compaction (LVNC) cardiomyopathies, which result from
mutations in one of several of the proteins that make up the car-
diac sarcomere. Here, we describe an approach to understand
the molecular basis of the alterations in power output that result910 Cell Reports 11, 910–920, May 12, 2015 ª2015 The Authorsfrom such mutations. We also show, studying one example of a
myosin small-molecule activator, that small molecules binding to
the mutant sarcomeric protein complex will be able to mitigate
the effects of hypertrophic and dilated cardiomyopathy muta-
tions at their sources, leading to new therapeutic approaches
for these genetic diseases.
Human a- and b-cardiacmyosins drive contraction of the heart
atria and ventricles, respectively (Lompre´ et al., 1984; Reiser and
Kline, 1998; Reiser et al., 2001). b-Cardiac myosin is a major site
for cardiomyopathy mutations; over 250 mutations in the b-car-
diac myosin motor domain have been reported as the cause of
cardiomyopathy diseases that disrupt the morphology and
proper functioning of the left ventricle, which delivers oxygen-
ated blood throughout the body (Bing et al., 2000; Colegrave
and Peckham, 2014; Harvey and Leinwand, 2011; Kimura,
2010; Marston, 2011). Although significant progress has been
made in understanding the effects of some cardiomyopathy mu-
tations from studies with animal models and patient biopsy sam-
ples (Cuda et al., 1997; Keller et al., 2004; Palmiter et al., 2000), a
detailed investigation of cardiomyopathy mutations at the
molecular level has been hampered by the lack of an expression
system with high yields of human cardiac myosin (Sata and
Ikebe, 1996).
In recent years, a mammalian expression system has been
developed for human striated muscle myosins that has made it
possible (1) to determine enzymatic differences between puri-
fied, homogeneous human a- and b-cardiac myosins and (2) to
study cardiomyopathy-causing mutations in the human b-car-
diac myosin backbone (Resnicow et al., 2010; Srikakulam and
Winkelmann, 1999). The human a- and b-cardiac motor domains
(subfragment 1 of myosin, or S1) can be expressed and purified
using this system (Deacon et al., 2012). Purified b-cardiac S1
demonstrates good actin-activated ATPase activity and dis-
places actin filaments in actin-gliding assays (Sommese et al.,
2013). Stopped-flow measurements have been performed to
determine the rates of transitions in the actin-myosin ATPase
cycle for these human cardiac S1s (Bloemink et al., 2014;
Deacon et al., 2012).
Cardiac myosin operates under varying loads in the heart; to
recapitulate the effect of cardiomyopathy mutations on cardiac
myosin’s function under physiological conditions, it is essential
to measure its power output under load. Thus, fundamental to
muscle contraction is the force-velocity curve, where the prod-
uct of the force and velocity at any point along the curve is a
measure of the power output. With increasing load, actin-gliding
velocity decreases and ultimately reaches zero when load is
equal to the maximal ensemble force (Daniels et al., 1984; Son-
nenblick, 1962).
The goal of this study is (1) to illustrate the effects of two car-
diomyopathy mutations on human cardiac myosin power output
with a reconstituted purified protein system and (2) to demon-
strate that screening of small compounds that restore mutant
cardiac myosin power output to wild-type (WT) levels is a
feasible path forward.
One way to measure actin-gliding velocities at different loads
is using a loaded in vitro motility assay in which increasing con-
centrations of an actin-binding protein is utilized as the load-
bearing molecule (Bing et al., 2000; Greenberg and Moore,
2010; Haeberle and Hemric, 1995; Warshaw et al., 1990). This
assay has been used to compare power output and maximal
force generation between myosin variants (Greenberg et al.,
2010; Haeberle, 1994; Malmqvist et al., 2004) and between
different solution conditions (Greenberg and Moore, 2010; Jan-
son et al., 1992). The assay is highly limited, however, by the
time it takes to analyze motility data and by an excessive amount
of user intervention and subjectivity in the analysis. Furthermore,
the current assay with a-actinin does not yield highly reproduc-
ible results with the motor domain S1, presumably due to the
small size of this domain compared to two-headed myosin con-
structs and the non-specific attachment of a-actinin on the sur-
face (Sommese et al., 2013).
Here, we present (1) in vitro motility analysis software that
rapidly performs actin filament tracking objectively with no user
intervention and (2) a customized loaded motility assay for
human cardiac short subfragment 1 (sS1; spans the N-terminal
motor domain and the ELC binding region in the lever arm)
with utrophin as the load molecule. To achieve proper control
of myosin and load molecule ratios, a truncated utrophin
construct of similar size to sS1 is engineered to anchor on a glass
surface via the same attachment used for sS1. Using these new
tools, we compare the WT forms of purified homogeneous hu-
man a- and b-cardiac sS1. In addition, we characterize two car-
diomyopathy mutations, M531R and S532P, which are adjacent
in the primary structure of b-cardiac myosin and are expected to
have very different effects on cardiacmyosin activity. M531R has
been found in patients with LVNC (Kaneda et al., 2008). S532P,
on the other hand, has been associated with DCM (Kamisago
et al., 2000). To assess whether our assay is sensitive to power
output changes due to binding of small molecules to cardiac
myosin, we characterize the effect of omecamtiv mecarbil (Malik
et al., 2011; Morgan et al., 2010), which is a previously discov-
ered cardiac myosin activator.
RESULTS
FAST Facilitates Unbiased, Automated, and Rapid
In Vitro Motility Data Analysis
A bottleneck limiting high-throughput data acquisition for in vitro
motility assays has been the lack of rapid, unbiased, and auto-
mated analysis software. Some automated filament trackingsoftware programs are packaged together with analog image-
acquisition systems (Homsher et al., 1992) not readily compat-
ible with state-of-the-art digital images. Also, we found the digital
analysis tools that are available (Ruhnow et al., 2011) do not have
the high throughput we seek for our studies and are not well opti-
mized for actin filament tracking. Here, we describe new actin
filament tracking and in vitro motility data analysis software,
FAST (Fast Automated Spud Trekker). FAST completes the anal-
ysis of a 30-frame in vitro motility movie in less than 30 s,
providing a detailed output. Graphical output of FAST has multi-
ple panels showing different aspects of the analysis (Figure 1;
see the Supplemental Experimental Procedures and Figure S1
for the tracking algorithm).
Maximum velocity (PLATEAU and TOP5%) is estimated from
a distribution that is filtered with respect to filaments with
fluctuating velocities (Figures 1A–1C; see the Supplemental
Experimental Procedures). Filtered (Figure 1B) and unfiltered
(Figure 1C) distributions are displayed in FAST output side by
side to show the effect of the filtering.
Another feature of FAST is to estimate the percentage of stuck
filaments (Figure 1C). Together with %STUCK, filament length
distribution (Figure 1D) is a useful metric in assessing the quality
ofmotility in unloaded conditions (see Experimental Procedures).
FAST output also displays how the mean of the velocity distri-
bution and TOP5% velocities change with decreasing tolerance
in filtering (Figure 1E).
Loaded In Vitro Motility Assay with Utrophin as the Load
Molecule Provides a Readout for Human Cardiac sS1’s
Ability to Overcome Load
For loaded in vitromotility, we designed a utrophin construct that
is similar in size to human b-cardiac sS1 (Figure S2) and
anchored on the surface via the same attachment system used
for human b-cardiac sS1 (Figure 2A). This allows proper mainte-
nance of myosin to load molecule ratios on the surface.
The new utrophin construct is ideal for loaded in vitro motility
as (1) it is stable as a monomer and (2) the range of utrophin con-
centrations required for actin-motility inhibition is low enough not
to compete with sS1 binding to SNAP-PDZ18.
Careful observation of movies revealed that with utrophin,
‘‘mobile filaments’’ become stuck at their front (minus) end,
remain immobile temporarily, and then continue gliding (see
Movies S1, S2, S3, and S4). Thus, filament velocities fluctuate
between unloaded velocities and zero, enhancing dispersion in
instantaneous velocities and decreasing average velocities (Fig-
ure 2B, unloaded versus 0.2 nM utrophin) due to utrophin. As the
duration of stops increases with increasing utrophin concentra-
tion, filaments remain immobile longer, trapping velocity values
around zero, thus causing dispersion in velocities to decrease
(Figure 2B, stuck).
The dispersion in path filament velocities and their average
values fall on a parabola, predicted by a stop model, and the
increase in utrophin concentration causes these points to
move along the parabola from high to low mean path-velocity
values (Figures 2C and 2D; see the Supplemental Experimental
Procedures). The velocity dispersion in unloaded conditions
(Figure 2C, 0 nM utrophin) is likely due to the small fraction of
dead heads that bind actin in rigor and halt gliding temporarily.Cell Reports 11, 910–920, May 12, 2015 ª2015 The Authors 911
Figure 1. The FAST Output for an Unloaded
Human b-Cardiac sS1 In Vitro Motility
Experiment
For this and all unloaded velocity experiments,
filaments tracked for at least ten consecutive
frames were included in the analysis, velocity and
filament lengths were averaged over five consec-
utive frames, a 20% tolerance filter was applied to
eliminate intermittently moving filaments with ve-
locities fluctuating higher than 20% of their mean
velocity, and stuck filaments were excluded from
the scatterplot analysis.
(A) Scatterplot of filament length and velocities.
Maximum velocity of each filament is in blue (tri-
angle), and lower velocities are in gray (circles).
The solid line is the fit to single exponential decay
function to the maximum velocities (blue) to obtain
the PLATEAU velocity. The dashed line marks the
mean of the top 5% velocities (TOP5%).
(B) A 20% tolerance-filtered filament velocity distri-
bution excluding stuck filaments. The linemarks the
mean of the filtered velocity distribution (MVEL20;
subscript 20 is for the percent tolerance value).
(C) The unfiltered filament velocity distribution excluding stuck filaments. The line marks the mean of the unfiltered distribution (MVEL). Filaments with a mean
velocity less than one pixel length per second (80 nm/s) are classified as stuck. %STUCK represents the time-weighted fraction of stuck filaments.
(D) Filament length distribution. The line marks the mean of the distribution.
(E) Mean of the velocity distribution (solid line) and TOP5% velocity (dashed line) from the data subjected to different levels of tolerance filtering (see the
Supplemental Experimental Procedures). Lower percent tolerance values indicate more stringent filtering allowing only filaments with smoother movement.
Asterisk (*) is for the unfiltered velocity distribution. See also Figure S1.Percent Time Mobile Is the Proper Measure for the
Assessment of Actin-Gliding Inhibition by Utrophin
We observe that both the time-weighted fraction of mobile fila-
ments (percent mobile filaments, Figure 3A) and the mean veloc-
ity of the unfiltered velocity distribution (MVEL, Figure 3B) decay
as a function of utrophin concentration. However, decay inMVEL
or percent mobile filaments alone does not capture the full
impact of utrophin. Effective utrophin surface density for the in-
hibition of mobile filaments is reduced due to filaments that are
relatively permanently bound to utrophin molecules; these utro-
phin molecules are no longer accessible to mobile filaments,
thus leading to overestimation of MVEL. Similarly, ‘‘percent
mobile filaments’’ overestimates the mobility of filaments, since
‘‘mobile filaments’’ do not glide at all times, remaining immobile
when bound to utrophin.
For proper assessment of filament mobility, we define
‘‘percent time mobile,’’ which is equal to the percent mobile fila-
ments corrected for the times spent as immobile (Figures 3A and
3B) and normalized by the unloaded TOP5% velocity (Figure 3C;
see the Supplemental Experimental Procedures).
The Stop Model Enables Comparison of Ensemble
Forces from Percent Mobile Data
To extract cardiac myosin ensemble force from percent mobile
data, a mathematical function that relates utrophin concentra-
tion to percent time mobile is required. We observe that percent
time stuck (100%  percent time mobile) normalized by percent
time mobile depends linearly on the utrophin concentration (Fig-
ure 3D). Writing normalized percent time stuck (also referred to
as stuck propensity) as a linear function of utrophin, we derive
an expression (Equation 1) that relates utrophin concentration
to percent time mobile with two parameters: (1) M0, which is
percent timemobile in the absence of utrophin; and (2) KS, which912 Cell Reports 11, 910–920, May 12, 2015 ª2015 The Authorsis analogous to KD (i.e., dissociation constant) used for binding
equilibrium relationships (for derivation, see the Supplemental
Experimental Procedures):
% time mobile=
KsM0
Ks + M0½utrophin: (Equation 1)
KS can be interpreted as the disassociation constant for the utro-
phin-actin interaction in the presence of cardiac sS1 on the sur-
face. We consider higher KS to indicate lower affinity between
utrophin and actin due to higher force generated by the cardiac
sS1 to break the utrophin-actin interaction.
This mathematical model (the stop model) fits better than a
single exponential fit when applied to b-cardiac sS1 percent
time mobile data (Figure 3C; see Figure S3A). As expected, we
observe that increases in cardiac sS1 concentration cause Ks
to increase, indicative of higher ensemble force due to higher
myosin density on the surface (Figure S3B).
Human a-sS1 Has 3-Fold Higher Maximal Velocity and
ATPase Rate but Generates Less Ensemble Force
Than b-sS1
Mammalians have two isoforms of cardiac myosin, a and b,
which are expressed in different ratios across different species
and in different sections of the heart (Lompre´ et al., 1984; Reiser
and Kline, 1998; Reiser et al., 2001). Using FAST and the new
loaded motility assay with utrophin, we compared human a-
and b-cardiac sS1, which are expected to have large differences
in their maximal unloaded velocities and ensemble forces based
on previous studies with animal and human a/b isoforms (Alpert
et al., 2002; Malmqvist et al., 2004; Noguchi et al., 2003;
VanBuren et al., 1995).
Figure 2. Utrophin Causes Actin Filaments to Glide with Intermittent
Stops in the Loaded In Vitro Motility Assay
(A) Cartoon representation of the loaded in vitro motility setup with human
b-cardiac sS1 and utrophin on a surface coated with the anchoring protein
SNAP-PDZ18 (light blue). Myosin (red) and utrophin (green) are anchored on
the surface via the same attachment system involving binding of a C-terminal
eight-residue peptide that specifically binds to the SNAP-PDZ18. Approxi-
mately 400-fold less utrophin (1 nM) than myosin (400 nM) is required to inhibit
actin filament (yellow) movement. Smoothly moving actin filaments encounter
utrophin at their front (minus) end and stopmoving temporarily (seeMovies S1,
S2, S3, and S4).
(B) Wild-type b-cardiac sS1 instantaneous velocity-time trajectories for an
unloaded actin filament (blue), a stuck filament (red), and a transiently loaded
filament (green) with utrophin. Dashed lines and error bars mark the meanHuman a-Cardiac sS1 Is a Faster Motor Than
b-Cardiac sS1
To assess whether human a- and b-cardiac sS1 have different
maximal velocities and catalytic activities, we measured the un-
loaded velocities (Figure 4A) and actin-activated ATPase rates
(Figure 4B) for the two human isoforms with the same lever
arm length (see Figure S4A). a-Cardiac sS1 showed 3-fold higher
maximum velocities than b. From theMichaelis-Menten equation
fit to actin-activated ATPase rates, a-cardiac sS1 showed a
3-fold higher maximal ATPase rate (kcat) and a 2-fold higher Km
than b, suggesting that a-cardiac sS1 has significantly lower
affinity for actin (Table S1; Figure 4B).
b-Cardiac sS1 Produces More Force Than a
To determine the ensemble force differences between a- and
b-cardiac sS1, we measured the utrophin-dependent percent
time mobile changes for the two isoforms. With increasing utro-
phin concentration, a-cardiac sS1 percent time mobile decays
more sharply than that of b-cardiac sS1, indicative of lower
ensemble force generation (Figure 4C). To determine the decay
parameter, KS, we fit the stop model to the percent mobile
data. From the fits, the a-cardiac sS1 KS is significantly lower
than the b-cardiac sS1 KS (Figure 4D; Table S1), indicating a
higher force for b-cardiac sS1.
In ventricles, there is 5% a-cardiac myosin, together with
95% b. To determine the effect of low levels of a-cardiac sS1
on b-cardiac sS1 velocities, we measured unloaded velocities
for a- and b-cardiac sS1 mixed at different ratios. From 0% to
10% a-cardiac sS1, we did not observe a significant change in
velocities.Also,weobserved that thea/b-cardiac sS1mixture ve-
locities deviated from linearitywith adownwardcurvature against
the fraction of a-cardiac sS1, indicating that b dominates a-car-
diac sS1 (Figure S4B), where downward curvature observed in
myosin-mixing experiments is generally attributed to lower force
generation by the titrated species (Harris et al., 1994; Warshaw
et al., 1990). This observation is in agreement with our results
froma- andb-cardiac sS1 loadedmotility experiments, indicating
that b-cardiac sS1 generates higher force than a.
Two Neighboring Cardiomyopathy Mutations, M531R
and S532P, Have Opposite Effects on Human b-Cardiac
Myosin Function
One aim for developing FAST and the new loaded in vitro motility
assay was for high-throughput maximal velocity and ensemble
force characterization of cardiomyopathy causing mutations in
the human b-cardiac myosin motor domain.velocity and the SD of instantaneous velocities, respectively, along the tra-
jectories. Unloaded and stuck intervals of the transiently loaded trajectory are
marked by blue and red, respectively, over the dashed mean velocity line.
(C) Effect of utrophin on gliding filaments is explained by a model in which
utrophin stops filament gliding at the maximal velocity (Supplemental Experi-
mental Procedures). Stars on the curve are for the unloaded (blue), stuck (red),
and transiently loaded (green) velocity trajectories in (B).
(D) Heatmaps show the probability density for experimental measurements of
filament mean velocity and velocity dispersion at different utrophin concen-
trations (upper left corner). The white solid line is for the best parabola fit to
aggregated probability densities from all utrophin concentrations. The yellow
vertical line marks the unloaded TOP5% velocity.
See also Figure S2.
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Figure 3. Percent Time Mobile Is the Mea-
sure of Actin-Gliding Inhibition by Utrophin
(A and B) Percent mobile filaments (A) and MVEL
(B) as a function of utrophin concentration.
(C) The stop model fits well to human b-cardiac
sS1 loaded in vitro motility percent time mobile
data. Percent time mobile is equal to the product
of percent mobile filaments (A) and MVEL (B)
normalized by unloaded TOP5% velocity. Blue
solid and black dashed lines are for the best stop
model and single exponential fits, respectively. KS
is indicated by the vertical dashed blue line.
Each loaded in vitro motility point is the average
from R1,000 filament tracks and R5,000 instan-
taneous velocities averaged over five frames.
Confidence intervals are the SEM from at least four
movie replicates.
(D) Alternative representation of b-cardiac sS1
loaded motility data as stuck propensity, which is
equivalent to percent time stuck (100%  percent
time mobile) divided by percent time mobile. Un-
loaded stuck propensity is subtracted from each
point. The line shows the best linear equation fit to
the data points. See also Figure S3.Maximal velocity and ensemble force directly determine myo-
sin’s maximal power output (Spudich, 2014). It has been hypoth-
esized that different classes of cardiomyopathy mutations may
change cardiac myosin’s power output differently leading to
different phenotypes (Sivaramakrishnan et al., 2009).
To illustrate the usefulness of the assay, we chose two cardio-
myopathy mutations, M531R and S532P, which are known to
cause LVNC and DCM, respectively (Kamisago et al., 2000; Ka-
neda et al., 2008). LVNC is associated with severe trabeculae
formation in the left ventricular wall and impaired systolic func-
tion (Udeoji et al., 2013), and DCM is associated with dilation
of the left ventricular wall and reduced systolic function (Hersh-
berger et al., 2013). The two mutations are located at the actin-
binding interface of the b-cardiac motor domain, most likely
affecting the actin-myosin interaction (Figure 5A).
The Human b-Cardiac Myosin Cardiomyopathy
Mutations M531R and S532P Are Gain- and
Loss-of-Function Mutations, Respectively
To determinewhether the twomutations have a strong impact on
human b-cardiac sS1, we performed in vitro motility (Figure 5B)
and actin-activated ATPase measurements (Figure 5C). M531R
has slightly lower maximum velocities than WT. On the other
hand, S532P has significantly depressed maximum velocities
as compared to WT (Table S1).
M531R and S532P have significantly higher and lower
maximal ATPase rates, respectively, than WT (Figure 5C; Table
S1). M531R and S532P have lower and higher Km values,
respectively, than WT, suggesting that M531R and S532P have
higher and lower affinity, respectively, for actin than WT.
M531R and S532P Generate Higher and Lower
Ensemble Force, Respectively, Than WT
We performed loaded in vitro motility measurements for M531R
and S532P with the utrophin-based assay to estimate their
ensemble force as compared to WT. Although M531R has914 Cell Reports 11, 910–920, May 12, 2015 ª2015 The Authorsslightly lower maximum 20% filtered velocities than WT (Fig-
ure 5B), it has a higher unloaded mean velocity than WT, since
M531R has a tighter velocity distribution concentrated closer
to maximum velocity values (Figure 5D). Having a tight velocity
distribution with significantly fewer filaments gliding at lower
velocities indicates that M531R is more efficient in overcoming
the internal load due to dead myosin heads in unloaded condi-
tions thanWT. From stopmodel fits, M531R has higher KS values
than WT, suggesting that M531R generates higher ensemble
force than WT, whereas lower KS values for S532P indicate
that S532P generates lower ensemble force than WT (Figures
5E and 5F; Table S1). These loaded in vitro motility results
with human b-cardiac myosin support the conclusion that
M531R and S532P are gain- and loss-of-function mutations,
respectively.
Omecamtiv Mecarbil Increases b-Cardiac sS1 Force
Generation but Decreases Unloaded Velocity
Amajor goal of cardiomyopathy research is to find therapies that
reverse or prevent disease progression and restore normal car-
diac function. We and others have shown that cardiomyopathy
mutations in cardiac myosin alter its power output, and it is
thought that the change in cardiac output triggers signaling cas-
cades leading to the disease phenotype (Sivaramakrishnan
et al., 2009; Spudich, 2014). It has been suggested that small
molecules that specifically interact with a cardiac sarcomeric
protein, including myosin itself, may restore cardiac function in
patients with cardiomyopathy mutations and reverse the effect
of those mutations (Sivaramakrishnan et al., 2009; Spudich,
2014).
Omecamtiv mecarbil (OM) is a small compound that was
discovered to bind specifically to cardiac myosin and enhance
cardiac output in animal models (Malik et al., 2011) and in
humans (Teerlink et al., 2011); however, demonstration of
Figure 4. a-Cardiac sS1 Has Nearly 3-Fold
Higher Actin-Activated Enzymatic Activity
and Unloaded Gliding Velocity but Gener-
ates Less Force Than b-Cardiac sS1
(A) Representative unloaded velocity scatterplots
for a- (left) and b-human cardiac sS1 (right), as
described in Figure 1. For description of lines, see
Figure 1A (a 20% tolerance filter was applied).
(B) Actin-activated ATPase rates for a (red) and b
(blue) human cardiac sS1. Solid lines show the
best Michaelis-Menten fits for the ATPase rates
(rate = kcat[actin]/(Km+[actin]). Dashed lines mark
the Km and half maximal ATPase rates (0.5 kcat).
Confidence intervals are the SEM from three
replicate measurements for each of three myosin
preparations.
(C) Representative loaded in vitro motility percent
time mobile data for a (red) and b (blue) human
cardiac sS1. Lines show the best stop model fit to
percent time mobile data. Dashed lines mark KS
values determined from the fit. Confidence in-
tervals are the SEM from at least four movie
replicates.
(D) Normalized a-cardiac sS1 motility parameters
(TOP5%, PLATEAU, KS; filled bars) and ATPase
(kcat, Km; empty bars) values with respect to
b-cardiac sS1. For unloaded motility parameters,
95% confidence intervals are the SEM from at
least four replicate movies from three different preparations of sS1. For KS, the 95% confidence interval is estimated from 100 iterations of stop model fitting
to bootstrapped data (Supplemental Experimental Procedures). For ATPase values, rates are the average of at least three replicates from three different
preparations of sS1 (Table S1).
See also Figure S4.increased force production with OM has not been achieved with
a purified reconstituted contractile system. Here, we use the
utrophin-based loaded in vitro motility assay to show that OM
does indeed increase human b-cardiac sS1 ensemble force
production.
First, to test whether OM affects human a- and b-cardiac sS1
similarly, we measured their unloaded velocities as a function of
OM concentration. Both a- and b-cardiac sS1 unloaded veloc-
ities drop sharply with OM (Figure 6A). It has previously been re-
ported that at saturating concentrations of OM, human (Liu et al.,
2013) and porcine b-cardiac myosin (Liu et al., 2015) unloaded
velocities drop several-fold. KD values determined from fitting
a binding isotherm to a- and b-cardiac sS1 unloaded velocity
data are within similar range (0.14–0.17 mM; see Table S1), sug-
gesting that OM binds to human a- and b-cardiac sS1 with
similar affinities.
To determine the ensemble force changes due to OM binding
to b-cardiac sS1, we performed loaded in vitro motility measure-
ments as a function of OM concentration. OM shifts the percent
time mobile data to higher values (Figure 6B), thus causing KS to
increase with OM (Figure 6C), which demonstrates that binding
of OM increases b-cardiac sS1 ensemble force.
DISCUSSION
Our results provide important insights into the functioning of hu-
man cardiac myosin, actin-binding proteins, and OM. Further-
more, we demonstrate that the utrophin-based loaded in vitro
motility assay more generally provides a quantitative platformto diagnose cardiomyopathy mutations and to screen for poten-
tial drugs that restore cardiac myosin function. This assay and
FAST analysis software are well designed for high-throughput
screening purposes.
Human a- and b-Cardiac sS1 Evolved to Function at
Different Force Ranges and Timescales
We show here that human a-cardiac sS1 is faster but generates
lower force than b. In the adult human heart, the cardiac myosin
composition is 95% b and 5% a in the ventricles and 5% b
and 95% a in the atria (Reiser et al., 2001). Ventricles are
responsible for pumping blood out of the heart and work against
higher loads than atria, which only aid the largely passive flow of
blood into the ventricles and contract over a shorter duration of
time than the ventricles. Our findings with human a- and b-car-
diac myosin are consistent with the idea that b-cardiac myosin
generates the high force required for ventricular contraction,
while the a isoform provides lower force but faster contraction
required for atrial function, and they are consistent with isometric
force measurements of myosin isolated from human atrial and
ventricular myocardium (Noguchi et al., 2003).
M531R and S532PMay Alter the Structural Organization
in the Human Cardiac sS1 Actin-Binding Interface,
Resulting in Opposite Phenotypes
Residues M531 and S532 are located on an a helix that is at the
actin-binding interface of human b-cardiac myosin (Figure 5A).
Both residues are highly conserved in the cardiac myosin family
(Figure S5). We showed that M531R and S532P have oppositeCell Reports 11, 910–920, May 12, 2015 ª2015 The Authors 915
Figure 5. M531R and S532P Have Opposite Impact on WT b-Cardiac sS1 Enzymatic and Mechanical Activity
(A) M531 (green) and S532 (orange) are side by side on the actin-binding interface. The inset shows a close-up of the mutation positions (for details of the
structural model, rendered using Pymol, see the Supplemental Experimental Procedures).
(B) Representative unloaded velocity scatter plots comparing PLATEAU and TOP5% velocities forWT (blue), M531R (green), and S532P (orange). For description
of lines, see Figure 1A (a 20% tolerance filter was applied).
(C) Actin-activated ATPase rates for WT b-cardiac sS1 (blue), M531R (green), and S532P (orange). For description of lines and estimation of confidence intervals,
see Figure 4B and Table S1 legend.
(D) Representative unfiltered velocity distributions comparing M531R b-cardiac sS1 (green) and WT (blue). MVEL values for M531R and WT are marked on the
velocity axis (inverted triangles). Velocity distributions are from four movies for WT and M531R collected on the same slide.
(E) Lines show the best stop model fit to unfiltered percent time mobile loaded motility data. Dashed lines indicate the KS determined from the fit. Confidence
intervals are the SEM from at least four movie replicates.
(F) M531R (green) and S532 (orange) motility (TOP5%, PLATEAU, KS; filled bars) and ATPase (kcat, Km; empty bars) values normalized to WT values. For esti-
mation of confidence intervals, see Figure 4D (legend) and Table S1.impacts on human cardiac myosin ATPase activity and mechan-
ical output, indicating that the two mutations may perturb the
structural arrangement in the actin-binding interface differently.
The lower Km and higher maximal ATPase rate for M531R sug-
gest that M531R leads to a conformational change favoring the
transition from the free to the actin-bound state of the motor;
oppositely, the higher Km and lower maximal ATPase rate for
S532P suggest that S532P disrupts the transition from the free
to the actin-bound state.
The M531 side chain is buried in the hydrophobic core of
the motor, while the S532 side chain is positioned near the
motor surface at the actin-binding site (Figure 7). Thermody-916 Cell Reports 11, 910–920, May 12, 2015 ª2015 The Authorsnamically, the positively charged mutant arginine side chain
at position 531 is not likely to be accommodated in the hydro-
phobic environment that the M531 residue normally resides in
(Harms et al., 2011). Sequence analysis of a representative
myosin universe indicates that only hydrophobic residues are
favored at position 531 (Figure S5). We expect the M531R
mutation to cause a structural perturbation in the a-helical
region exposing the arginine side chain in solution, in a
conformation favoring arginine interaction with the negatively
charged actin interface, promoting actin binding. On the other
hand, we expect the S532P mutation to deform the actin-bind-
ing interface by destabilizing the a helix, since proline is an
Figure 6. Omecamtiv Mecarbil Binding to Cardiac sS1 Increases
Ensemble Force Generation but Decreases Its Unloaded Velocity
(A) MVEL decreases with increasing concentration of omecamtiv mecarbil for
both a- (red, inset) and b-cardiac (blue) sS1. Lines show the best binding
isotherm fit to data (Supplemental Experimental Procedures). Dashed lines
mark the KD determined from the fits. Confidence intervals are the SEM from at
least four movie replicates.
(B) Representative loaded in vitro motility data for b-cardiac sS1 at different
concentrations of omecamtiv mecarbil (d, 0 mM;:, 0.25 mM;;, 0.5 mM;-,
2 mM). Increase in color intensity indicates increase in omecamtiv mecarbil
concentration. Solid lines are for the best stop model fits to percent time
mobile data. Dashed lines mark KS determined from the fits. Confidence in-
tervals are the SEM from at least four movie replicates.
(C) KS determined from stop model fits to b-cardiac sS1 loaded motility data.
95% confidence intervals are estimated from 100 iterations of stop model
fitting to bootstrapped data (Supplemental Experimental Procedures).
Figure 7. TheMutationsM531R and S532P Are Likely to Cause Local
Structural Changes with a Major Impact on the Actin-Myosin
Interaction
Local environments of M531 (green) and S532 (orange) correlate with the
sequence conservation profiles in Figure S6. Both positions are on an a helix in
close proximity to a patch of negatively charged residues (red) on actin. M531
(green) is buried in the hydrophobic core, and S532 (orange) is exposed to
solvent. See also Figure S5.a-helix breaker (Pace and Scholtz, 1998). From the sequence
analysis, we also found proline not to be favored at position
532 (Figure S5).Increased Force Generation by OMMay Offset Its Effect
in Unloaded Velocity Reduction
It was previously shown that OM binds to the myosin catalytic
domain and operates by an allosteric mechanism to increase
the transition rate of myosin into the strongly actin-bound
force-generating state and enhances systolic force generation
in animal models, thus increasing cardiac power output (Malik
et al., 2011). Recent studies show that additional effects at the
molecular level include a nearly 20-fold decrease in actin-gliding
velocity and a 2-fold decrease in the actin-activated ATPase of
porcine b-cardiac myosin at saturating OM (Liu et al., 2015).
Strongly bound (to actin) state time (referred as ts) and total
ATPase cycle time (referred as tc) are inversely proportional to
unloaded velocity and the actin activated ATPase rate, respec-
tively. Therefore, such changes in velocity and ATPase rate
would indicate a 20-fold increase in ts and a 2-fold increase
in tc, resulting in a 10-fold increase in the duty ratio ts/tc, which
would be predicted to result in increased ensemble force (Spu-
dich, 2014). Our results showing increased force generation
with OM at the molecular level are consistent with those obser-
vations. The reduction in unloaded velocity by OM seen here
and previously reported (Liu et al., 2013, 2015) is unexpected
and perhaps could be explained by an OM-based decrease on
a load-dependent ADP release rate. Such an effect could
lengthen the strongly bound state time of the myosin head,
further increasing the duty ratio, leading to a further increase in
force production.
Perhaps related to this putative decrease in load-dependent
ADP release rate is the finding that OM prolongs the systolic
phase of the contraction, which is thought to be the primary
cause of myocardial ischemia observed in some human subjects
(Teerlink et al., 2011). This side effect wasmore pronounced with
human subjects carrying 3 mM (1,200 ng/ml) OM, which was the
highest concentration tested. Our results indicate that OM leadsCell Reports 11, 910–920, May 12, 2015 ª2015 The Authors 917
to a dose-dependent increase in ensemble force from 0 to 2 mM.
This is in the range of the therapeutic window for OM function
in vivo.
The increase in ensemble force by OM apparently offsets
the decrease in velocity, resulting in an overall increase in
power output (p = F 3 v) seen in treated patients (Teerlink
et al., 2011).
EXPERIMENTAL PROCEDURES
Expression and Purification of Human Cardiac Myosin in C2C12
Cells
For steady-state ATPase measurements and in vitro motility gliding assays,
two different human cardiac short S1 (sS1) constructs, one with a C-terminal
EGFP tag and the other with C tag (-RSTIDVW) were used, respectively. For
both constructs, a flexible GSG linker separates sS1 from the C-terminal tag
(see Figure S2). The human a-cardiac sS1 constructs span residues 1–810.
The human b-cardiac sS1 constructs span residues 1–808. The cloning,
expression, and purification of the EGFP-tagged construct is described else-
where (Sommese et al., 2013). C-tagged constructs were cloned, expressed,
and purified similarly. The only difference is that 10% sucrose was added to
the human cardiac sS1 preparations after elution from the Q-column to keep
the myosin more stable. The human cardiac sS1 retains its motility properties,
our most sensitive test of stability, when flash frozen in liquid nitrogen and
stored at 80C in 10% sucrose. After purification, EGFP-tagged constructs
were exchanged into ATPase assay buffer conditions using Amicon centrifugal
filter units (Millipore).
Expression and Purification of Utrophin and Other Actin-Binding
Proteins
The pDEST17 plasmid encoding the first 416 residues of mouse utrophin was a
gift from David Thomas’ laboratory (University of Minnesota). Using this
plasmid, the utrophin construct with C tag (see Figure S2) was designed and
cloned into a pet47-b vector. The new construct has an N-terminal 6X-his
tag for nickel affinity purification. The final plasmid was transformed into the
Rosetta (DE3) bacterial cell line for protein expression (see the Supplemental
Experimental Procedures).
Expression and Purification of SNAP-PDZ18
The SNAP-PDZ18 fusion construct has an N-terminal 10X-his tag and FLAG
tag and a FLAG-tag linker between SNAP and the PDZ18, which is at the C ter-
minus. SNAP-PDZ18 was cloned into a pHFT2 plasmid for expression. SNAP-
PDZ18 was expressed and purified using nickel affinity chromatography
following the same protocol as for the purification of PDZ18 (Huang et al.,
2009) (see the Supplemental Experimental Procedures).
Preparation of Other Proteins and Materials
Expression and purification of full-length human gelsolin is described else-
where (Sommese et al., 2013). Bovine actin, which is identical in protein
sequence to human actin, was a gift from MyoKardia. OM, the structure of
which was confirmed by nuclear magnetic resonance andmass spectrometry,
was a gift from Leslie Leinwand.
Unloaded and Loaded In Vitro Motility Measurements
The motility assay was as described previously (Kron et al., 1991), with mod-
ifications described in the Supplemental Experimental Procedures. Reagents
were loaded in the following order: (1) SNAP-PDZ18, incubated 2 min; (2) BSA
to block the surface from nonspecific subsequent attachments, incubated
2 min; (3) a mixture of C-tagged human cardiac sS1 and utrophin, incubated
for 3 min; (4) ABBSA (defined in Sommese et al., 2013) to wash the channels;
and (5) tetramethylrhodamine (TMR)-phalloidin-labeled bovine actin, ATP, an
oxygen-scavenging system, and an ATP-regeneration system. Movies were
obtained as described in the Supplemental Experimental Procedures. Assays
for each cardiac sS1 variant were repeated with at least three fresh protein
preparations. At each condition, at least four movies of 30 s duration were re-918 Cell Reports 11, 910–920, May 12, 2015 ª2015 The Authorscorded. While there was some prep-to-prep variability in absolute velocities,
the relative differences between WT b-cardiac sS1 and the a-isoform or
mutants were preserved. To minimize any systematic errors due to batch-
to-batch differences in C2C12 cells, when the a-cardiac sS1 or the mutant
b-cardiac sS1s were prepared, a fresh WT b-cardiac sS1 was prepared in par-
allel. For measurements with OM, OM is diluted in AB and incubated with car-
diac sS1 for 10 min on ice before loading, then included in all buffers such that
the final concentrations of the OM in the motility assay buffer is as indicated in
the figures.
Actin-Activated Steady-State ATPase Measurements
Actin-activated steady-state ATPase measurements were performed as
described previously (Sommese et al., 2013) but using bovine cardiac actin.
Human cardiac sS1 that was EGFP tagged was used. The absorbance of
EGFP allowed accurate measurement of the concentration of human cardiac
sS1. Actin-activated ATPase measurements for each human cardiac sS1
variant were repeated with at least three fresh myosin preparations.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, one table, and fourmovies and can be foundwith this article online
at http://dx.doi.org/10.1016/j.celrep.2015.04.006.
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